Nucl Med Commun. 2021 Nov 01;42(11):1202-1208. doi: 10.1097/MNM.0000000000001455.

Clinical impact of targeted single-photon emission computed tomography/computed tomography (SPECT/CT) bone scintigraphy on the assessment of bone metastasis in cancer patients.

Nuclear medicine communications

Nikolaos Kapsoritakis, Maria Stathaki, Olga Bourogianni, Angeliki Tsaroucha, Emmanouela Papadaki, Panagiotis Simos, Sophia Koukouraki

PMID: 34149007 DOI: 10.1097/MNM.0000000000001455

Abstract

OBJECTIVES: We investigated the clinical impact of single-photon emission computed tomography/computed tomography (SPECT/CT) bone scintigraphy combined with 16-slice CT on metastatic workup and treatment planning in a large cancer patient series.

METHODS: Between January 2019 and January 2020, a total of 600 cancer patients were prospectively evaluated with whole-body planar bone scan (wbPBS) for staging or restaging purposes. 272/600 had equivocal lesions on wbPBS and 265/272 underwent additionally a targeted SPECT/CT bone scintigraphy on designated regions. Findings were classified as benign (score 1), metastatic (score 2) and inconclusive (score 3). Findings from SPECT/CT bone scintigraphy were compared with the results of wbPBS.

RESULTS: A total of 668 lesions were considered as unclear οn wbPBS and were re-evaluated through targeted SPECT/CT bone scintigraphy. Definite diagnostic findings on SPECT/CT bone scintigraphy were obtained in 227/265 (85.7%) patients and in 592/668 (88.6%) lesions vs. 15.4% of wbPBS alone. On per-patient analyses, 38.9% of patients were considered definitely nonmetastatic and 46.8% as definitely metastatic. On per lesion analyses using SPECT/CT bone scintigraphy, corresponding diagnostic rates were 47.5 and 41.2%. Although the addition of SPECT/CT bone scintigraphy significantly reduced the rate of equivocal wbPBS results (83.1%), it failed to provide a conclusive diagnosis in a relatively small proportion of lesions 76/668 (11.4%) in 38 patients.

CONCLUSIONS: SPECT/CT bone scintigraphy afforded a significant reduction of the number of patients with equivocal findings who needed further evaluation with other imaging modalities, preventing unnecessary delays in diagnosis and potential changes in disease staging and treatment planning. Moreover, SPECT/CT bone scintigraphy slightly increased diagnostic sensitivity.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

References

1. Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, Goncalves F. Bone Metastases: An Overview. Oncol Rev 2017; 11:321. - PubMed
2. Liu T, Wang S, Liu H, Meng B, Zhou F, He F, et al. Detection of vertebral metastases: a meta-analysis comparing MRI, CT, PET, BS and BS with SPECT. J Cancer Res Clin Oncol 2017; 143:457–465. - PubMed
3. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 2005; 46:1356–1367. - PubMed
4. Cook GJ, Goh V. Functional and Hybrid Imaging of Bone Metastases. J Bone Miner Res 2018; 33:961–972. - PubMed
5. Savelli G, Maffioli L, Maccauro M, De Deckere E, Bombardieri E. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med 2001; 45:27–37. - PubMed
6. Apostolova I, Gölcük E, Bohuslavizki KH, Buchert R, Brenner W. Impact of additional SPECT in bone scanning in tumor patients with suspected metastatic bone disease. Ann Nucl Med 2009; 23:869–875. - PubMed
7. Shafi A, Thorsson O, Edenbrandt L. New routine for nuclear medicine technologists to determine when to add SPECT/CT to a whole-body bone scan. J Nucl Med Technol 2014; 42:28–32. - PubMed
8. Gnanasegaran G, Barwick T, Adamson K, Mohan H, Sharp D, Fogelman I. Multislice SPECT/CT in benign and malignant bone disease: when the ordinary turns into the extraordinary. Semin Nucl Med 2009; 39:431–442. - PubMed
9. Saha S, Burke C, Desai A, Vijayanathan S, Gnanasegaran G. SPECT-CT: applications in musculoskeletal radiology. Br J Radiol 2013; 86:20120519. - PubMed
10. Tuncel M, Lay Ergun E, Caglar Tuncali M. Clinical impact of SPECT-CT on bone scintigraphy in oncology: pattern approach. J BUON 2016; 21:1296–1306. - PubMed
11. Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Türler A, et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging 2014; 41:59–67. - PubMed
12. Zhao Z, Li L, Li F, Zhao L. Single photon emission computed tomography/spiral computed tomography fusion imaging for the diagnosis of bone metastasis in patients with known cancer. Skeletal Radiol 2010; 39:147–153. - PubMed
13. Langsteger W, Rezaee A, Pirich C, Beheshti M. 18F-NaF-PET/CT and 99mTc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer. Semin Nucl Med 2016; 46:491–501. - PubMed
14. O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol 2015; 7:202–211. - PubMed
15. Guezennec C, Keromnes N, Robin P, Abgral R, Bourhis D, Querellou S, et al. Incremental diagnostic utility of systematic double-bed SPECT/CT for bone scintigraphy in initial staging of cancer patients. Cancer Imaging 2017; 17:16. - PubMed
16. Römer W, Nömayr A, Uder M, Bautz W, Kuwert T. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med 2006; 47:1102–1106. - PubMed
17. Helyar V, Mohan HK, Barwick T, Livieratos L, Gnanasegaran G, Clarke SE, Fogelman I. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging 2010; 37:706–713. - PubMed
18. Zacho HD, Aleksyniene R, Ejlersen JA, Fledelius J, Petersen LJ. Inter and intraobserver agreement in standard and ultra fast single photon emission computed tomography/computed tomography for the assessment of bone metastases. Nucl Med Commun 2020; 41:1005–1009. - PubMed

Publication Types

• Journal Article